Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Ruxolitinib

2

XVII.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

1
Last update : 17/03/2014
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Ruxolitinib dicontinuation/withdrawal
1

Publications

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib.
Case reports in hematology 2016;2016;2389038 2016
Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis.
Leukemia & lymphoma 2015 May;56;1528-9 2015 May
Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge.
Annals of hematology 2015 Mar;94;519-20 2015 Mar
Ruxolitinib Associated Tuberculosis Presenting as a Neck Lump.
Case reports in infectious diseases 2015;2015;284168 2015
Disseminated tuberculosis associated with ruxolitinib.
Leukemia 2014 Aug;28;1750-1 2014 Aug
Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report.
BMC research notes 2012 Oct 05;5;552 2012 Oct 05

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies